Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)

Date

02 Dec 2023

Session

Poster Display

Presenters

Rongbo Lin

Citation

Annals of Oncology (2023) 34 (suppl_4): S1502-S1519. 10.1016/annonc/annonc1378

Authors

R. Lin1, S. Zhao1, L. Su1, Y. Hong2, J. Luo3, Y. Wei4, S. Zhao5

Author affiliations

  • 1 Gi Oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 2 Medical Oncology, Quanzhou First Hospital, 362000 - Quanzhou/CN
  • 3 Medical Oncology, Fujian Rehabilitation hospital, fuzhou/CN
  • 4 Medical Oncology/hematology, Wuping County Hospital, longyan/CN
  • 5 Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, 350014 - Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 128TiP

Background

Immune-checkpoint inhibitors (ICI) show modest activity and efficacy in patients with MSS mCRC and pMMR. A recent trial of botensilimab (next-generation anti–CTLA-4 antibody) + balstilimab (anti-PD-1 antibody) for heavily pretreated pMMR/MSS mCRC reported promising results. Cadonilimab is a humanized bi-specific antibody that targets both PD-1 and CTLA-4. Its higher binding avidity in a tumor-like setting and Fc-null design may increase drug retention in tumors and improve safety. A more intensive chemotherapy, FOLFOXIRI + bevacizumab, can enhance the antitumor effect of ICI by increasing tumor immunogenicity. AtezoTRIBE, a phase II study, showed that adding atezolizumab to first-line FOLFOXIRI + bevacizumab might improve progression-free survival (PFS) in patients with mCRC. Therefore, in this study we aim to investigate the efficacy and safety of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for patients with unresectable pMMR/MSS mCRC.

Trial design

This is a multicenter single arm phase II study. Eligibility criteria include: histologically or cytologically confirmed pMMR/MSS mCRC; age 18-75 years; naive to systemic treatment in the metastatic setting; at least 1 measurable lesion according to RECIST 1.1; ECOG PS 0-1; and adequate organ function. Patients with high microsatellite instability (MSI-H) tumors and those who previously received immunotherapy are excluded. Twenty eligible participants will receive FOLFOXIRI (intravenous [i.v.] irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 48-h infusion) + bevacizumab 5 mg/kg i.v. and cadonilimab 6 mg/kg i.v. Treatment is administered for up to twelve 14-day cycles followed by maintenance with fluorouracil and leucovorin (or capecitabine) + bevacizumab and cadonilimab for a total of 52 weeks or until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint is objective response rate per RECIST 1.1. Secondary endpoints are PFS, overall survival, and safety. Enrollment is ongoing.

Clinical trial identification

NCT05839470.

Legal entity responsible for the study

The authors.

Funding

Akeso, Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.